New York, NY -- (SBWIRE) -- 12/19/2017 -- Dengue Vaccine Market 2017

The Aedes aegypti mosquito is responsible for transmitting the dengue virus (DENV). The virus that causes dengue belongs to the Flavivirus genus of the Flaviviridae family. Dengue fever resembles influenza and affects adults, children, as well as infants, but it is rarely fatal. However, dengue hemorrhagic fever is a potentially fatal complication because of multiple factors such as fluid accumulation, severe bleeding, organ impairment, or plasma leaking. The scientific community hypothesizes that the DENV evolved in nonhuman primates from where it spread to humans first in Southeast Asia and Africa and then to other parts of the world.

The analysts forecast the global dengue vaccine market to grow at a CAGR of 15.05% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global dengue vaccine market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/2578066-global-dengue-vaccine-market-2017-2021

The report, Global Dengue Vaccine Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- GlaxoSmithKline
- Merck Sharp & Dohme
- Sanofi
- Takeda Pharmaceuticals

Other prominent vendors
- GeneOne Life Sciences
- Medigen Biologics
- Panacea Biotec
- Sun Pharmaceutical

Market driver
- Rapid growth in disease prevalence
- For a full, detailed list, view our report

Market challenge
- Regulatory hurdles in vaccine penetration
- For a full, detailed list, view our report

Market trend
- Licensing deals
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?

Any Query, Submit Here @ https://www.wiseguyreports.com/enquiry/2578066-global-dengue-vaccine-market-2017-2021

Table of Contents –Analysis of Key Points

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
- Market outline

PART 05: MARKET LANDSCAPE
- Market overview
- Market size and forecast

PART 06: FIVE FORCES ANALYSIS
PART 07: PIPELINE ANALYSIS
PART 08: MARKET SEGMENTATION BY END-USER
- Government institutions
- Hospitals
- NGOs

PART 09: MARKET SEGMENTATION BY VACCINE TYPE
- Live attenuated vaccines
- Inactivated vaccines

PART 10: REGIONAL LANDSCAPE
- Regional comparison
- Dengue vaccine market in Americas
- Dengue vaccine market in EMEA
- Dengue vaccine market in APAC
- Market opportunity

PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges

PART 13: MARKET TRENDS
- Licensing deals
- Growing awareness
- Advances in diagnostic techniques
- Novel approach to eliminate dengue

PART 14: VENDOR LANDSCAPE
PART 15: KEY VENDOR ANALYSIS
- GlaxoSmithKline
- Merck Sharp & Dohme
- Sanofi Pasteur
- Takeda Pharmaceuticals
- Other prominent vendors
..…..Continued